Abstract
HGF is a mesenchyme-derived pleiotropic factor, which regulates cell growth, cell motility, and morphogenesis of various types of cells and is thus considered a humoral mediator of epithelial-mesenchymal interactions responsible for morphogenic tissue interactions during embryonic development and organogenesis. Although HGF was originally identified as a potent mitogen for hepatocytes, it has also been identified as a member of angiogenic growth factors. Interestingly, the presence of its specific receptor, c-met, is observed in vascular cells and cardiac myocytes. In addition, among growth factors, the mitogenic action of HGF on human endothelial cells was most potent. Recent studies have demonstrated the potential application of HGF to treat cardiovascular diseases such as peripheral vascular disease, myocardial infarction and cerebrovascular disease. In this review, we will discuss a potential therapeutic strategy using HGF in cardiovascular disease.
Keywords: angiogenesis, restenosis, gene therapy, peripheral vascular disease, myocardial infarction
Current Gene Therapy
Title: Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF)
Volume: 4 Issue: 2
Author(s): Ryuichi Morishita, Motokuni Aoki, Naotaka Hashiya, Keita Yamasaki, Hitomi Kurinami, Shiro Shimizu, Hirofumi Makino, Yasushi Takesya, Junya Azuma and Toshio Ogihara
Affiliation:
Keywords: angiogenesis, restenosis, gene therapy, peripheral vascular disease, myocardial infarction
Abstract: HGF is a mesenchyme-derived pleiotropic factor, which regulates cell growth, cell motility, and morphogenesis of various types of cells and is thus considered a humoral mediator of epithelial-mesenchymal interactions responsible for morphogenic tissue interactions during embryonic development and organogenesis. Although HGF was originally identified as a potent mitogen for hepatocytes, it has also been identified as a member of angiogenic growth factors. Interestingly, the presence of its specific receptor, c-met, is observed in vascular cells and cardiac myocytes. In addition, among growth factors, the mitogenic action of HGF on human endothelial cells was most potent. Recent studies have demonstrated the potential application of HGF to treat cardiovascular diseases such as peripheral vascular disease, myocardial infarction and cerebrovascular disease. In this review, we will discuss a potential therapeutic strategy using HGF in cardiovascular disease.
Export Options
About this article
Cite this article as:
Morishita Ryuichi, Aoki Motokuni, Hashiya Naotaka, Yamasaki Keita, Kurinami Hitomi, Shimizu Shiro, Makino Hirofumi, Takesya Yasushi, Azuma Junya and Ogihara Toshio, Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF), Current Gene Therapy 2004; 4 (2) . https://dx.doi.org/10.2174/1566523043346453
DOI https://dx.doi.org/10.2174/1566523043346453 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of Long Chain n-3 PUFA on Endothelial Activation, Endothelial Function and Atheromatous Plaque Stability
Current Nutrition & Food Science Treatment of Mild Cognitive Impairment (MCI)
Current Alzheimer Research Soluble RAGE-Modulating Drugs: State-of-the-Art and Future Perspectives for Targeting Vascular Inflammation
Current Vascular Pharmacology Cerebrovascular Diseases in HIV-Infected Patients
Current HIV Research Combinational Approaches Targeting Neurodegeneration, Oxidative Stress, and Inflammation in the Treatment of Diabetic Retinopathy
Current Drug Targets Ethnicity and Inflammatory Pathways - Implications for Vascular Disease, Vascular Risk and Therapeutic Intervention
Current Medicinal Chemistry The Role of Niacin in Lipid-lowering Treatment: Are we Aiming Too High?
Current Pharmaceutical Design Vascular Biomarkers in Asthma and COPD
Current Topics in Medicinal Chemistry Harnessing Polypharmacology with Computer-Aided Drug Design and Systems Biology
Current Pharmaceutical Design Effects of Endothelins on Cardiac and Vascular Cells: New Therapeutic Target for the Future?
Current Vascular Pharmacology Pleiotropic Effects of Statins - Clinical Evidence
Current Pharmaceutical Design Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Dev elopment (Part C))
Current Pharmaceutical Design Long Term Cardiovascular Risk in Women
Vascular Disease Prevention (Discontinued) Biomarkers Associated with Vulnerable Atheromatous Plaque
Current Medicinal Chemistry Growth Restriction: Etiology, Maternal and Neonatal Outcome. A Review
Current Women`s Health Reviews Vascular Risk Factors and Alzheimer’s Disease Pathogenesis: Are Conventional Pharmacological Approaches Protective For Cognitive Decline Progression?
CNS & Neurological Disorders - Drug Targets Antenatal Maternal Antidepressants Drugs Affect S100B Concentrations in Fetal-Maternal Biological Fluids
CNS & Neurological Disorders - Drug Targets Anti-Thrombotic Properties of Tomato
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Milk Thistle: A Future Potential Anti-Osteoporotic and Fracture Healing Agent
Current Drug Targets Adenoid Hypertrophy, Craniofacial Growth and Obstructive Sleep Apnea: A Crucial Triad in Children
Current Respiratory Medicine Reviews